C07C2601/14

USE OF PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY

This disclosure relates to picolinamides of Formula I and their use as fungicides.

##STR00001##

HYDROSILANE/LEWIS ACID ADDUCT, PARTICULARLY ALUMINUM, IRON, AND ZINC, METHOD FOR PREPARING SAME, AND USE OF SAID SAME IN REACTIONS FOR REDUCING CARBONYL DERIVATIVES
20180009730 · 2018-01-11 ·

Disclosed is an adduct between a Lewis acid, preferably aluminum trichloride, iron trichloride, or zinc dichloride, and a hydrosilane;—a method for preparing same; and a method for for reducing, particularly, an aldehyde, a ketone, an α,β-unsaturated ketone, an imine, or an α,β-unsaturated imine.

Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

##STR00001##

Inhibitors of the WNT/beta-catenin pathway

The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.

Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers

Provided herein are compounds of the formulas: ##STR00001##
wherein: n, X.sub.2, R.sub.3, R.sub.3′, R.sub.4, R.sub.4′, R.sub.5, R.sub.5′, R.sub.6, and R.sub.6′ are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.

Protease inhibitors for treatment of coronavirus infections

Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4, R.sup.5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (M.sup.pro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

Sulfuric acid ester or salt thereof, and surfactant

A sulfuric acid ester containing a plurality of carbonyl groups or a salt thereof, and a surfactant. The sulfuric acid ester is a compound represented by the following formula:
R.sup.1—C(═O)—R.sup.2—C(═O)—R.sup.3—OSO.sub.3X
wherein R.sup.1, R.sup.2 and R.sup.3 are defined herein; X is H, a metal atom, NR.sup.4.sub.4, imidazolium optionally containing a substituent, pyridinium optionally containing a substituent, or phosphonium optionally containing a substituent, where R.sup.4s are each H or an organic group and are the same as or different from each other; and any two of R.sup.1, R.sup.2, and R.sup.3 optionally bind to each other to form a ring. Also disclosed is a surfactant containing the sulfuric acid ester and an aqueous dispersant containing the sulfuric acid ester.

PHARMACEUTICAL COMPOSITION WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY
20180008717 · 2018-01-11 ·

A composition comprising a compound having a formula I:

##STR00001##

wherein T is derivative of a terpene and R is a derivative of a neurotransmitter acids, wherein the neurotransmitter acids are selected form GABA, glycine, and taurine. Pharmaceutical formulations for oral and topical use as analgesics and anti-inflammatories are also provided. A process for preparing the composition and the formulations are also provided.

YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4

Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and sternness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.

ASPARAGINE DERIVATIVES AND METHODS OF USING SAME

The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

##STR00001##